• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.

作者信息

Wei Fangqiang

机构信息

Department of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.

出版信息

Lancet Gastroenterol Hepatol. 2022 Jun;7(6):504. doi: 10.1016/S2468-1253(22)00083-8.

DOI:10.1016/S2468-1253(22)00083-8
PMID:35550049
Abstract
摘要

相似文献

1
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.可切除肝细胞癌的新辅助免疫治疗
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):504. doi: 10.1016/S2468-1253(22)00083-8.
2
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply.可切除肝细胞癌的新辅助免疫治疗——作者回复
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):505. doi: 10.1016/S2468-1253(22)00122-4.
3
Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?".回复：“肝细胞癌患者接受免疫治疗的预后预测：我们做到了吗？”
J Hepatol. 2022 Apr;76(4):988-989. doi: 10.1016/j.jhep.2021.12.025. Epub 2021 Dec 31.
4
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal.肝移植前肝细胞癌的新辅助治疗：批判性评估
Liver Transpl. 2006 Dec;12(12):1747-54. doi: 10.1002/lt.21018.
5
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.可切除肝细胞癌的辅助和新辅助治疗。
Curr Oncol Rep. 2023 Oct;25(10):1191-1201. doi: 10.1007/s11912-023-01455-9. Epub 2023 Sep 9.
6
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指标。
J Hepatol. 2022 May;76(5):1232-1233. doi: 10.1016/j.jhep.2021.12.033. Epub 2022 Jan 19.
7
Down-staging of hepatocellular carcinoma before liver transplantation: should we change our clinical practice?肝移植前肝细胞癌的降期：我们是否应该改变临床实践？
Ann Surg. 2009 Aug;250(2):348; author reply 348-9. doi: 10.1097/SLA.0b013e3181b1e72a.
8
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".回复：“CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指南”。
J Hepatol. 2022 May;76(5):1233-1234. doi: 10.1016/j.jhep.2022.02.002. Epub 2022 Feb 14.
9
HCC-neuroendocrine transition: Tumor plasticity under immunotherapy.肝癌-神经内分泌转化：免疫治疗下的肿瘤可塑性
Gastroenterol Hepatol. 2022 Aug-Sep;45(7):552-554. doi: 10.1016/j.gastrohep.2022.01.008. Epub 2022 Feb 2.
10
Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive HCC Resulting in Complete Pathologic Response.新辅助放疗、肺叶切除术及免疫疗法治疗血管浸润性肝癌并获得完全病理缓解
Hepatology. 2021 Jul;74(1):525-527. doi: 10.1002/hep.31675. Epub 2021 Apr 27.

引用本文的文献

1
NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.自然杀伤细胞介导静脉注射卡介苗对小鼠肺转移的预防作用。
Cancer Gene Ther. 2025 Aug 2. doi: 10.1038/s41417-025-00948-y.
2
CircZCCHC2 (hsa_circ_0000854) promotes hepatocellular carcinoma progression through modulating miR-936/BTBD7 axis and activating Rho/ROCK2 pathway.环状锌指蛋白2（hsa_circ_0000854）通过调控miR-936/BTBD7轴和激活Rho/ROCK2通路促进肝细胞癌进展。
Noncoding RNA Res. 2023 Dec 28;9(2):437-446. doi: 10.1016/j.ncrna.2023.12.004. eCollection 2024 Jun.
3
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.
二甲双胍对根治性治疗后 2 型糖尿病合并肝细胞癌患者生存结局的影响。
Front Endocrinol (Lausanne). 2022 Dec 13;13:1060768. doi: 10.3389/fendo.2022.1060768. eCollection 2022.